ESPOSITO, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.525
EU - Europa 9.012
AS - Asia 7.894
SA - Sud America 950
Continente sconosciuto - Info sul continente non disponibili 236
AF - Africa 150
OC - Oceania 16
Totale 36.783
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.081
GB - Regno Unito 2.765
IT - Italia 2.598
CN - Cina 2.313
SG - Singapore 2.274
SE - Svezia 1.020
HK - Hong Kong 931
BR - Brasile 737
VN - Vietnam 736
DE - Germania 596
UA - Ucraina 444
FI - Finlandia 419
TR - Turchia 409
BD - Bangladesh 301
FR - Francia 294
RU - Federazione Russa 274
KR - Corea 263
CA - Canada 237
IN - India 208
BG - Bulgaria 146
NL - Olanda 109
AR - Argentina 80
MX - Messico 77
ZA - Sudafrica 59
IQ - Iraq 55
LT - Lituania 55
ID - Indonesia 50
PL - Polonia 46
IE - Irlanda 43
JP - Giappone 40
PK - Pakistan 40
IR - Iran 39
CO - Colombia 34
ES - Italia 33
AE - Emirati Arabi Uniti 31
BE - Belgio 29
CR - Costa Rica 28
PH - Filippine 26
EC - Ecuador 25
JM - Giamaica 25
EU - Europa 24
IL - Israele 24
CL - Cile 21
UZ - Uzbekistan 21
MY - Malesia 20
VE - Venezuela 18
AT - Austria 17
CH - Svizzera 17
EG - Egitto 17
JO - Giordania 16
PE - Perù 16
SA - Arabia Saudita 16
MA - Marocco 15
AU - Australia 13
HN - Honduras 13
DZ - Algeria 12
KE - Kenya 12
TH - Thailandia 12
GR - Grecia 10
RO - Romania 10
RS - Serbia 10
CZ - Repubblica Ceca 9
KZ - Kazakistan 9
PA - Panama 9
PY - Paraguay 9
DK - Danimarca 8
DO - Repubblica Dominicana 8
KG - Kirghizistan 8
PR - Porto Rico 8
PT - Portogallo 8
SV - El Salvador 8
AL - Albania 7
GT - Guatemala 7
NI - Nicaragua 7
TN - Tunisia 7
TT - Trinidad e Tobago 7
AZ - Azerbaigian 6
EE - Estonia 6
NO - Norvegia 6
SI - Slovenia 6
TW - Taiwan 6
ET - Etiopia 5
GE - Georgia 5
KW - Kuwait 5
LV - Lettonia 5
NP - Nepal 5
SK - Slovacchia (Repubblica Slovacca) 5
UY - Uruguay 5
AM - Armenia 4
LB - Libano 4
MD - Moldavia 4
OM - Oman 4
QA - Qatar 4
SN - Senegal 4
BO - Bolivia 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
CW - ???statistics.table.value.countryCode.CW??? 3
MG - Madagascar 3
NZ - Nuova Zelanda 3
Totale 36.530
Salva come PNG Salva come JPEG
Città #
Ashburn 2.638
Southend 2.066
Santa Clara 1.636
Singapore 1.489
Fairfield 1.105
Woodbridge 1.011
Chandler 918
Hong Kong 904
Jacksonville 797
Hefei 787
Houston 683
San Jose 664
Dearborn 572
Nyköping 514
Wilmington 497
Beijing 487
Council Bluffs 457
Ann Arbor 449
Seattle 392
Cambridge 374
London 342
Los Angeles 339
Chicago 309
Milan 269
Helsinki 263
Seoul 249
Izmir 245
New York 234
Ho Chi Minh City 214
Rome 203
The Dalles 195
Hanoi 167
Buffalo 156
Princeton 147
Dallas 146
Sofia 138
Eugene 135
São Paulo 133
San Diego 123
Modena 119
Salt Lake City 118
Lauterbourg 111
Des Moines 105
Naples 97
Shanghai 96
Frankfurt am Main 88
Toronto 83
Moscow 80
Tampa 65
Munich 58
Orem 53
Elk Grove Village 52
Montreal 50
Boardman 48
Philadelphia 48
Bologna 47
Columbus 47
Da Nang 46
Palermo 43
Atlanta 42
Bari 41
Florence 39
Warsaw 38
Nanjing 37
Guangzhou 35
Bremen 34
Haiphong 33
Brooklyn 32
Dublin 32
Phoenix 32
Chennai 31
Kent 30
Tokyo 30
Turin 30
Redwood City 29
Verona 29
Catania 28
Mexico City 28
Sterling 28
Mumbai 27
Ottawa 27
Johannesburg 26
Boston 25
Brescia 24
Detroit 24
Brussels 23
Kunming 23
Amsterdam 22
Augusta 22
Jakarta 22
San Mateo 22
Baghdad 21
Denver 21
Falkenstein 21
Norwalk 21
Lancaster 20
Memphis 20
Miami 20
Miano 20
Parma 20
Totale 25.030
Salva come PNG Salva come JPEG
Nome #
Un raro caso di prostatite da Candida albicans, Candida krusei ed Enterococcus fecium 1.961
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 522
Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors 440
Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients 419
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. 405
Identification and characterization of an aspartyl protease from Cryptococcus neoformans 398
Autologous fat transfer for the treatment of HIV-related face lipoatrophy: A long follow-up experience 385
Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy 380
Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study 379
La clinica metabolica per il trattamento della lipodistrofia 369
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients 367
Gram-positive bloodstream infections in liver transplant recipients: incidence, risk factors, and impact on survival. 361
Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients 359
Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study 354
The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans 354
Efficacy and safety of atazanavir in patients with end-stage liver disease. 351
Alendronate treatment for osteoporosis in patients infected with human immunodeficiency virus. 351
Body image is a major determinant of sexual dysfunction in stable HIV-infected women. 331
Long-term psychometric outcomes of facial lipoatrophy therapy: Forty-eight-week observational, nonrandomized study 331
Mitochondrial DNA Haplogroups and Highly Active Antiretroviral Therapy–Related Lipodystrophy 327
Fatal cytomegalovirus necrotising enteritis in a small bowel transplantation adult recipient with low pp65 antigenaemia levels 325
Different sensitivity to apoptosis in cells of monocytic or lymphocytic origin chronically infected with human immunodeficiency virus type-1 320
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital 318
Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. 318
Outcome, incidence, and timing of infections in small bowel/multivisceral transplantation 316
Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naive HIV-positive patients. 315
Autologous fat transfer for the treatment of HIV-related face lipoatrophy: 1-year follow-up 314
Alendronate reduces bone turnover in HIV-associated Osteopenia and Osteoporosis 311
Detectable HIV viral load is associated with metabolic syndrome 311
Autologous fat transfer for treating facial wasting in HIV body fat redistribution syndrome. 310
Gli ascessi epatici nei pazienti sottoposi a trapianto ortotopico di fegato 310
Differential Dose Adjustments of Immunosuppressants after Resuming Boosted versus Unboosted HIV-Protease Inhibitors Postliver Transplant. 310
Psychometric evaluation of patients undergoing surgical treatment of HIV-related facial lipoatrophy 309
Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection 309
Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy 307
Prevalence of secondary causes of osteoporosis among HIV infected individuals 305
Brucellosis in a patient with end-stage liver disease undergoing liver transplantation: successful treatment with tigecycline. 304
Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy 300
Assessment of 10-year probability of a major osteoporotic fracture in HIV-infected patients using FRAX® tool algorithms. 300
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: An international observational study 300
Raltegravir and enfuvirtide as a “bridge” antiretroviral therapy in kidney-tranplanted patients with HIV infection receiving everolimus and low-dose cyclosporine: a case-control study 297
Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. 293
Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases. 292
Applicazione della scala di valutazione, Functional indipendence Measure (FIM), per la valutazione dei programmi di riabilitazione per pazienti affetti da AIDS Dementia Complex ospiti di una casa alloggio 290
Late presenters in an HIV surveillance system in Italy during the period 1992-2006. 288
Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR 288
Dietary evaluation and metabolic alterations in HIV-related lipodystrophy 287
MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection. 286
Autologous fat transfer for treating facial wasting in HIV-related lipodystrophy: experience of 53 treated patients 285
Severity of lipodystrophy is associated with decreased health-related quality of life 284
Prospective, partially randomized, 24-week study to compare the efficacy and durability of different surgical techniques and interventions for the treatment of HIV-related facial lipoatrophy 283
Immunophenotype of HIV plus patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system 282
Bloodstream infections (BSIs) in Liver Transplant Recipients: Analisys at an Italian Tertiary-Care Hospital 281
Association of serum vitamin D levels nd type 2 diabetes in HIV infection in the Modena cohort 280
Un caso di tubercolosi post-trapianto ortotopico di fegato: limiti dell’impiego del quantiferon-TB gold nella diagnosi della infezione tubercolare latente ed attiva 279
Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation 278
Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. 272
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 10(6) cells/I 271
Artropodi vettori di agenti infettivi 271
Prevalence of and risk factors for pubic lipoma development in HIV-infected persons 270
Body Image is a major determinant of sexual dysfunction in stable HIV-infected women. 270
Long-term follow-up of graft hypertrophy after autologous fat transfer for HIV-related face lipoatrophy (hamster syndrome 1 year later) 267
Age-related comorbidities in people living with HIV 266
Prevalence and risk factors of pubic lipomas in HIV-infected patients 263
Determinants of erectile dysfunction changes in HIV infected men: a prospective study. 263
Alendronate for the treatment of Osteoporosis in HIV-infected patients. 260
Psychometric evaluation in patients undergoing fillers injections for the treatment of HIV-related facial lipoatrophy: polylactic acid versus polyacrylamide 259
Improving the appropriateness of antibiotic prescription in hospitals: a pilot study assessing the effectiveness of an infectious diseases specialist's consultation programme 257
Efficacy and safety of medical and surgical interventions for treating HIV-related lipodystrophy in women 256
Candidemia nosocomiale: quattro anni di esperienza in un'ospedale universitario italiano 255
Erectile dysfunction does not mirror sub-clinical atherosclerosis in HIV infected males. 248
Does change of the liver change the metabolism? Assessment of atazanavir pharmacokinetic profile in 7 HIV-infected patients pre- and post-liver transplantation 248
Long lasting psycho-social benefits of polyacrylamide injections for the treatment of facial lipoatrophy 248
Morphologic alterations in HIV infected people with lipodystropy are associated with good adherence to HAART. 240
Does lipodistrophy affect quality of life? 239
Autologous fat transfer for treating facial waisting in HIV body fat redistribution Syndrome 238
Body Image perception in HIV infected women with body fat redistribution. 236
Posttransplant Mycobacterium tuberculosis disease following liver transplantation and the need for cautious evaluation of quantiferon TB GOLD results in the transplant setting: A case report 234
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: The CARe study 228
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 225
First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006) 225
Invasive pulmonary and cerebral aspergillosis in a patient with Weil's disease 223
GH response to GH-releasing hormone-arginine (GHRH+Arg) is impaired in women affected by human immunodeficiency virus (HIV)-related lipodystrophy 222
Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: Report of three cases 217
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3. 217
CD4-Guided treatment interruptions: a new possibile therapeutic strategy 216
Longitudinal assessment of pre-transplant mortality risk among HIV-infected and uninfected patients with end-stage liver disease: the role of delta-meld score 216
Statistical agreement between metabolic syndrome ATP-III, IDF, EGIR and ACE classification in HIV-infected patients and association with body fat redistribution 215
Pharmacokinetic interaction between amprenavir/ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation 214
The role of virological and immunological parameters on the diagnosis of metabolic syndrome in HIV-associated lipodystrophy 213
È possibile un counselling HIV su internet? 212
Different dose adjustments of immunosuppresants are necessary after initiating boosted or unboosted first protease inhibitors regimen post-liver transplantation 211
Body fat redistribution syndrome in HIV infected people is associated with good adherence to HAART 210
Mechanical and ultrasound-assisted liposuction for treating subcutaneous fat accumulations in HIV-related lipodystrophy: experience of 33 treated patients 209
Pathological fractures in patients with osteopenia and osteoporosis induced by antiretroviral therapy 206
Statistical agreement between ATPIII, IDF, EGIR, AACE metabolic syndrome classifications in HIV-infected patients and association with lipodystrophy 206
Lipodystrophy and quality of life: a prospective study 206
Validity of body image perception in women with HIV. 204
La trasmissione verticale di HIV nell’era della HAART 204
Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: The changes in opportunistic prophylaxis study 203
Totale 30.262
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.361
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.361
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.692 0 0 0 246 53 85 118 177 220 134 367 292
2022/20232.854 300 261 229 240 316 467 46 288 333 55 166 153
2023/20241.739 111 139 122 176 283 151 149 199 52 60 104 193
2024/20255.789 219 94 93 387 1.230 791 461 287 658 258 619 692
2025/202610.111 674 477 893 1.237 1.715 756 1.000 489 985 828 633 424
2026/20273.436 283 580 977 1.596 0 0 0 0 0 0 0 0
Totale 36.783